- Breadth and function of antibody response to acute SARS-CoV-2 infection in humans 26 February 2021 Kuan-Ying A Huang
- Molecular and electrophysiological features of spinocerebellar ataxia type seven in induced pluripotent stem cells 24 February 2021 Richard J Burman
- Alzheimer's Risk Gene TREM2 Determines Functional Properties of New Type of Human iPSC-Derived Microglia 22 February 2021 Marvin Reich
- Genome-wide CRISPR/Cas9-knockout in human induced Pluripotent Stem Cell (iPSC)-derived macrophages 20 February 2021 Elena Navarro-Guerrero
- Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2 4 February 2021 Jiandong Huo
- Tissue-resident macrophages regulate lymphatic vessel growth and patterning in the developing heart 19 January 2021 Thomas J Cahill
- Honing the Double-Edged Sword: Improving Human iPSC-Microglia Models 28 December 2020 Anne Hedegaard
- SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus 8 December 2020 Monique I Andersson
- TREM2 Alzheimer's variant R47H causes similar transcriptional dysregulation to knockout, yet only subtle functional phenotypes in human iPSC-derived macrophages 17 November 2020 Hazel Hall-Roberts
- Interferon-stimulated gene products as regulators of central carbon metabolism 13 November 2020 Kourosh H Ebrahimi
DPhil Student | email@example.com
Szymon is a DPhil student in Interdisciplinary Bioscience (BBSRC DTP in collaboration with Eli Lilly).
Neurodegenerative diseases, especially Alzheimer’s and Parkinson’s, affect millions of people worldwide. Unfortunately, there has been little to no success in developing treatments to prevent the onset or slow the progress of these diseases. Inflammation within the central nervous system can affect the course of neurodegenerative diseases, but – at the moment – we lack a representative human in vitro system to suitably mirror the neuroinflammatory state. Induced Pluripotent Stem Cells (iPSCs) can be generated from human donor skin or blood cells and turned into different brain cell types.
Szymon’s project will address the above limitation by culturing different human iPSC brain cell types together in a three-dimensional scaffold, including brain immune cells, microglia. This will enable us to study neuroinflammation and neurodegeneration ‘in a dish’. Szymon graduated from The University of Nottingham (MSci Neuroscience). During his studies, he developed an interest in cell culture models by working on in vitro conditions which could promote stem cell characteristics in cancer cells (thanks to Dr Dr. Androutsellis-Theotokis). During a placement year at the Alzheimer’s Research UK Drug Discovery Institute at University College London, he was focusing on culturing primary rat microglia in serum free conditions (thanks to Dr Lorenza Magno). When finishing off the time in Nottingham, his MSci thesis indicated that a polygenic risk score generated from microglial genes can partly predict the risk of developing Alzheimer’s disease (thanks to Prof Kevin Morgan).